/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

X4 Pharmaceuticals Inc Share Price Today: Live Updates & Key Insights

X4 Pharmaceuticals Inc share price today is $3.85, up -10.39%. The stock opened at $4.27 against the previous close of $4.33, with an intraday high of $4.27 and low of $3.875.

X4 Pharmaceuticals Inc Share Price Chart

style
pb-0

X4 Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

X4 Pharmaceuticals Inc Share Price Performance

$3.85 -0.1039(-10.39%) XFOR at 13 Mar 2026 03:56 PM Biotechnology
Lowest Today 3.875
Highest Today 4.27
Today’s Open 4.27
Prev. Close 4.33
52 Week High 10.50
52 Week Low 1.35
Day’s Range: Low 3.875 High 4.27
52-Week Range: Low 1.35 High 10.50
1 day return -
1 Week return +2.91
1 month return +13.95
3 month return +2.64
6 month return +29.33
1 year return +1112.5
3 year return +326.37
5 year return -58.5
10 year return -

X4 Pharmaceuticals Inc Institutional Holdings

FMR Inc 9.72

Bain Capital Life Sciences Investors, LLC 9.11

Saturn V Capital Management LLC 6.63

Kalehua Capital Management LLC 4.26

Vanguard Group Inc 3.92

Fidelity Small Cap Growth 3.87

BRAIDWELL LP 3.85

Rosalind Advisors, Inc. 2.98

Trails Edge Capital Partners, LP 2.94

Nantahala Capital Management, LLC 2.80

Morgan Stanley Inception 2.79

Morgan Stanley Inst Inception I 2.79

Vanguard Total Stock Mkt Idx Inv 2.69

Bvf Inc 2.55

Fidelity Select Biotechnology 2.38

Samsara BioCapital, LLC 2.24

Fidelity Small Cap Growth K6 1.93

EQ/Morgan Stanley Small Cap Growth K 1.82

Siren, L.L.C. 1.72

Fidelity Advisor Biotechnology I 1.53

Deep Track Capital, LP 1.28

Woodline Partners LP 1.14

StemPoint Capital LP 1.03

Vanguard Institutional Extnd Mkt Idx Tr 1.02

Stonepine Capital Management Llc 0.68

Fidelity Extended Market Index 0.49

SILVERARC CAPITAL MANAGEMENT, LLC 0.41

Blackrock Extended Mkt Fund CF 0.25

Extended Equity Market Fund K 0.21

Pale Fire Capital SE 0.19

Fidelity Total Market Index 0.19

UBS Group AG 0.18

Affinity Asset Advisors, LLC 0.17

Fidelity Series Total Market Index 0.16

NT Ext Equity Mkt Idx Fd - L 0.11

NT Ext Equity Mkt Idx Fd - NL 0.09

Spartan Extended Market Index Pool F 0.09

Spartan Total Market Index Pool G 0.08

Schwab Total Stock Market Index 0.08

Vanguard Instl Ttl Stck Mkt Idx Tr 0.07

X4 Pharmaceuticals Inc Market Status

Strong Buy: 3

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

X4 Pharmaceuticals Inc Fundamentals

Market Cap 378.60 M

PB Ratio 6.6196

PE Ratio 0.0

Enterprise Value 333.76 M

Total Assets 146.45 M

Volume 308427

X4 Pharmaceuticals Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:3000000 3.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:3000000 3.0M, FY19:null 0.0M

Annual Net worth FY23:-111141000 -111.1M, FY22:-93867000 -93.9M, FY21:-88696000 -88.7M, FY20:-62131000 -62.1M, FY19:-56604000 -56.6M

Quarterly Revenue Q3/2025:1765000 1.8M, Q2/2025:1973000 2.0M, Q1/2025:28807000 28.8M, Q3/2024:560000 0.6M, Q2/2024:563000 0.6M

Quarterly Profit Q3/2025:1414000 1.4M, Q2/2025:1647000 1.6M, Q1/2025:24091000 24.1M, Q3/2024:333000 0.3M, Q2/2024:295000 0.3M

Quarterly Net worth Q3/2025:-29815000 -29.8M, Q2/2025:-25741000 -25.7M, Q1/2025:282000 0.3M, Q3/2024:-36696000 -36.7M, Q2/2024:90833000 90.8M

About X4 Pharmaceuticals Inc & investment objective

Company Information X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 143

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow